HeartWare International — Merger or Acquisition (September 2015)
42 slides from HeartWare International's merger presentation, Sep 1, 2015
Slide 1: HeartWare Exhibit 99.7
Exhibit 99.7 HeartWere
Slide 2: Advancing Our Leadership in Advanced Heart Failure
Advancing Investor 2September HeartWare® and1, Our Analyst Valtech 2015 Technology Conference Leadership Call and in Webcast Advanced Heart Failure
Slide 3: Safe Harbor Forward-Looking Statements
Safe Forward-Looking This and performance, statements, Valtech development technology; these reliance assume information, regulations or materially number HeartWare’s Part HEARTWARE, SEC. VALTECH, expectations expectations II, Harbor announcement forward-looking Item any products; of onfrom risks fo
Slide 4: Additional Information and Participants in the Solicitation
Participants HeartWare, proposed SEC information interests Additional A the statement/prospectus documents new joint onholding April proxy intransaction. Shareholder Information may the Valtech regarding in30, the proposed statement/prospectus company also 2015. Solicitation and be (when Athe and In
Slide 5: List of Participants
List ofKarl-Heinz Doug Peter Amir Maisano, Prof. Francesco McAree Gross Godshall Participants M.D. Founder Senior Zurich President Chair Head and Vice of ofCardiovascular CEO, and Cardiology President CEO, Valtech HeartWare and Department, Cardio Surgery, CFO, HeartWare International University Askl
Slide 6: Doug Godshall, President and CEO, HeartWare
President DOUG HEARTWARE, CHORDALGODSHALL andand CEO, HVAD, Valtech HeartWare MVAD, logos are International PAL, trademarks SYNERGY, of Valtech CIRCULITE Cardio, Ltd. and HeartWare logos are trademarks of HeartWare, Inc. or its affiliates. 6 VALTECH, CARDIOBAND, CARDINAL, CARDIOVALVE and V-
Slide 7: HeartWare Mission and HVAD System Track Record
9000+ Patients Implanted Mission 46 We revolutionary treatment patients HVAD® Note: Record HEARTWARE, VALTECH, Intl. create Data ~120 to U.S. Globally System—A of Countries Centers get asCARDIOBAND, heart technology of back HVAD, June ~175 failure toCenters Proven 30, life. MVAD, to for 2015. allow
Slide 8: HeartWare Advances Mission with Valtech Transaction
HeartWare Advanced Advance advanced Leverage with valve Expand potential Accelerate $250M Deepen experiences tricuspid Drive value HEARTWARE, VALTECH, potential disease creation Shareholder transcatheter Our mitral valve Our Competitive heart Heart Our +CARDIOBAND, to Team: Market Valtech: Mission:
Slide 9: Strategic Market and Team Fit
Strategic Market Team Customer Patients Portfolio Focus 6Provider HVAD® MVAD® Advanced BTT >600 Robust VAD Will Partial-support Full-support 4Cardinal Stages Heart Cardiac >60 Significant Over Mitral Tricuspid HEARTWARE, 9VALTECH, HeartWare® Technologies, product employees serve and 40% Market emplo
Slide 10: Multiple Mitral and Tricuspid Solutions Needed
Multiple Mitral Complex 21M Portfolio Note: HEARTWARE, CHORDAL 2ultiple population Stuge & Tools Regurgitation approaches Tricuspid of disease solutions 2006 and solution HVAD, Valtech Significantly JTCS, Regurgitation: underserved Tricuspid Solution MVAD, logos Rogersare needed Regurgitation 2009 P
Slide 11: Current Treatment Landscape for Mitral and Tricuspid
Current Available Not Mitral Tricuspid U.S. Low Repair Surgical Transcatheter Repair* High *Replacement Source: HEARTWARE, VALTECH, 11 HeartWare® EUAvailable Prevalence Surgical Surgical Only. Regurgitation Repair Treatment Nkomo Repair Surgical Today Regurgitation CARDIOBAND, for Replacement Transc
Slide 12: Cardinal and V-Chordal Surgery Products
Cardinal™ Cardinal Surgery semi-rigid, Dynamic system Allows heart precise CE Transfemoral HEARTWARE, products VALTECH, Marked, study under for sizing bi-lateral V-Chordal mitral n=30, all annuloplasty & echocardiography CARDIOBAND, innovative, in V-Chordal®: user-levels andPost-Market and HVAD, com
Slide 13: Cardioband: Commercial-Stage Transfemoral Annuloplasty
Cardioband®: Gold-standard European –Cardioband Tricuspid HEARTWARE, CHORDAL 50+ the 6Real implant Transfemoral patients beating FIM commercial sizes Mitral designed and implanted Commercial-Stage annuloplasty -time expected HVAD, Valtech CE patient, heart as launch Mark aMVAD, late logos tosafe, ad
Slide 14: Cardioband: Surgical-Like Repair, Less Invasively
Cardioband: Surgical-Like Surgical Based Benefits Potentially Replicates Does –Enables Predictable Differentiated HEARTWARE, CHORDAL 14 HeartWare® Supra-annular Preserves Potential Leaflets not onfuture Annuloplasty Relative prevent Proven intact surgical docking better procedure valve’s and Potenti
Slide 15: CardioValve: Transseptal Mitral Replacement
CardioValve™: Transseptal Proven Designed Orientation-indifferent Low steerability Potential profile transseptal to synergy based Delivery and be one Starting transapical onofcapabilities of well-established Cardioband-CardioValve system first shape With transseptal options with Endfive invalve Mind
Slide 16: Strategic Rationale
Strategic Create Strengthen HeartWare Extensive Outreach Reach Accelerate Into HEARTWARE, CHORDAL Interventional theRationale: toMCS Leading Expansion Ability field cardiologists and and HVAD, team Valtech to cardiologists •A valve Valtech •possesses •New Surgical Valtech MVAD, logos more center Por
Slide 17: Amir Gross, Founder and CEO, Valtech Cardio
FounderGROSS AMIR HEARTWARE, CHORDAL andand CEO, HVAD, Valtech Valtech MVAD, logos Cardio, arePAL, trademarks Ltd.SYNERGY, of Valtech CIRCULITE Cardio, Ltd. and HeartWare logos are trademarks of HeartWare, Inc. or its affiliates. 17 VALTECH, CARDIOBAND, CARDINAL, CARDIOVALVE and V-
Slide 18: Valtech's Early Appreciation of HeartWare Team and Culture
Valtech’s Early Appreciation Strong Stock HEARTWARE, HeartWare transaction alignment Chosen forHVAD, HeartWare’s investment further Path: of entrepreneurial HeartWare MVAD, aligns enabled achievements interests PAL, Team, cultures creation SYNERGY, and Culture with and allows of ashared VADs and str
Slide 19: Valtech: Products and Team
Valtech: Products –•Team HEARTWARE, CHORDAL Leveraging Near-term Serving Experienced Proven Annuloplasty Valve Chord Multiple Portfolio 62 Exceptional Since deep; 2010: replacement repair Valve execution multiple broad commercial-stage potentially revenue and proven 4R&D; Expertise FIM HVAD, Valtech
Slide 20: Valtech Product Pipeline and Platforms
Product Including Platform CE annuloplasty Surgical chordae Pending Adjustable transcatheter repair Tricuspid Mitral Transfemoral Transcatheter replacement HEARTWARE, Transapical Preclinical VALTECH, Mark Transatrial / Transcatheter Pipeline: repair CE and Product (2011) /Two Mitral surgical CARDIOB
Slide 21: Valtech Portfolio: Comprehensive Interventional Solutions
Valtech Mitral Tricuspid U.S. Functional ~3.2M Low Cardinal Risk Surgical Replacement Cardioband High Cardiovalve Transcatheter Source: HEARTWARE, VALTECH, 21 HeartWare® Prevalence Surgical Surgical Regurgitation ~1.0M Portfolio: Nkomo Solutions Surgical Surgical Regurgitation Degenerative V-Chordal
Slide 22: Prof. Francesco Maisano, M.D.
Chair ofFRANCESCO PROF. HEARTWARE, CHORDAL Cardiovascular and HVAD, Valtech MAISANO, Surgery, MVAD, logos arePAL, University trademarks M.D. SYNERGY, Hospital of Valtech CIRCULITE of Zurich Cardio, Ltd. and HeartWare logos are trademarks of HeartWare, Inc. or its affiliates. 22 VALTECH, CARDIOBAND,
Slide 23: Heart Failure Patient Journey and Treatment Paradigm
Heart From Future Outcomes NYHA Clinic Outpatient Medical Cardinal Management Cardioband Stage CardioValve Inotrope Time HEARTWARE, VALTECH, Failure ISetting II III IV Heart EARLY LVAD UseDiagnosis CARDIOBAND, Failure HTx Patient Inpatient MID HVAD, Hospitalization Care Journey: LATE MVAD, / Paradig
Slide 24: Tailored Market Opportunity: Mitral and Tricuspid
Tailored Market Surgical Mitral ~60% 2p–1Functional Tricuspid Regurgitation No surgical-risk Note: HEARTWARE, VALTECH, roblem, Ventricle repair •75% Native Degenerative options Stuge of •& of Etiologies gold Surgeons Treatment annuloplasty structural cases Tricuspid 25% population population MitraCl
Slide 25: Cardinal: Utilization and Adjustability
Cardinal: Utilization Adjustability 100% 90% On- 80% 50% Adjusted Pump Percentage 20% Coaptation 0% 10% If Note: HEARTWARE, CHORDAL Adjusted 0Adjusted Not (mm) of Maisano 12 4 cases 7.7 Pump Off- Coaptation of +32% 30% 2When and Off-Pump-Only Cardinal Off- 62013 Adjusted HVAD, Only Valtech Patients
Slide 26: Cardioband: Adjustability on a Beating Heart
Cardioband: Baseline Transfemorally Real-time heart Reduction lateral Final reduction Proven adjustment leveraged interventional HEARTWARE, VALTECH, adjustability Size (A-P) surgical Cardioband post- for /Cardioband ofbeating CARDIOBAND, Adjustability diameter septo- system concept HVAD,Pre-Adjustme
Slide 27: Prof. Karl-Heinz Kuck, M.D., Ph.D.
Head ofKARL-HEINZ PROF. Cardiology Department, KUCK, M.D., Asklepios PH.D.Klinik St. Georg, Hamburg, Germany
Slide 28: Structural Heart Market
Structural Primary Estimated Aortic Surgical ~1M TAVR 1.0M Left failure Tricuspid degenerative Mitral 1.6M Right and Regurgitation Other 4.2M replacement Varies indication repair aortic Note: Source: U.S. HEARTWARE, VALTECH, ~8,000 heart mitral Census Stenosis •Tricuspid Aortic and stenosis •Tricusp
Slide 29: Cardioband: Core Lab Efficacy and Safety Results
Cardioband: Cardioband Core 88% Efficacy 100% 12 80% 0-1+ Patients 40% procedural 2+ Percentage 3-4+ Note: HEARTWARE, CHORDAL months 2+Safety •MR 0-1+ No 3-4+ Lab; Nickenig patients 2+ Favorable septo-lateral 2+ Dr. •mortality requirement 20% 20% MR and Safe 80% Paul have PCR HVAD, •Reduction Valtec
Slide 30: Mitral Valve Repair and Replacement: Complementary Therapies
Mitral valve Durability, Safety, Transcatheter Source: HEARTWARE, CHORDAL including Maisano safety and isValve replacement not HVAD, Valtech 2015 avoidance and just Therapies: disruption European a MVAD, logos valve, may of are permanent Complementary itbe of PAL, Heart istrademarks an adjacent a co
Slide 31: Peter McAree, Senior Vice President and CFO
Senior Vice PETER HEARTWARE, CHORDAL MCAREE President and HVAD, Valtech andMVAD, logos CFO,are HeartWare PAL, trademarks SYNERGY, International of Valtech CIRCULITE Cardio, Ltd. and HeartWare logos are trademarks of HeartWare, Inc. or its affiliates. 31 VALTECH, CARDIOBAND, CARDINAL, CARDIOVALVE and
Slide 32: Investment Highlights
Investment Combined Uniquely Heart Event-rich Growth Appreciably Addition Differentiated Value Substantially Risk-Mitigating Structure Capital Sufficient HEARTWARE, CHORDAL Failure Creation Efficient Platform of preserves Attractive cash portfolio company Highlights: high-gross-margin and scales acc
Slide 33: Deal Structure: Transaction Terms and Milestones
Deal Creation, Valtech 2015-2025 2015 Event shares ?Payments CE 800K Portfolio Breadth Repair HEARTWARE, VALTECH, Closing Milestone Earn-out Cardioband Mark, Structure: 2016 shares and Tricuspid Products WW and Mitral Preserves or shares ?2017 CARDIOBAND, Close, Transcatheter CardioValve Revenue FIM
Slide 34: Illustrative Valtech Revenue Growth
Accelerated Illustrative $800M Weighted-Average $900 $800 ($M) Revenue $500 $400 $300 Valtech Total $140M $200 2020 $0 $100 Note: HEARTWARE, VALTECH, $600 Transcatheter $700 Market 42% & 2025 $75-$200 Graph Replacement Revenue, Repair Surgical Growth: CAGR Transcatheter Revenue CARDIOBAND, Growth de
Slide 35: Transaction Terms Summary
Acquisition Clinical –10-year Earn-out Transaction Merger New Subject Timing Hart-Scott-Rodino Shareholder HEARTWARE, VALTECH, 35 HeartWare® 800,000 700,000 850,000 $375M U.S. structured to term and period in holding shares warrants regulatory of Terms stock Summary Structure CARDIOBAND, vote revenu
Slide 36: Doug Godshall, President and CEO, HeartWare
President DOUG HEARTWARE, CHORDALGODSHALL andand CEO, HVAD, Valtech HeartWare MVAD, logos are International PAL, trademarks SYNERGY, of Valtech CIRCULITE Cardio, Ltd. and HeartWare logos are trademarks of HeartWare, Inc. or its affiliates. 36 VALTECH, CARDIOBAND, CARDINAL, CARDIOVALVE and V-
Slide 37: HeartWare Core Business: Momentum
HeartWare Transaction driven extension by record ofCore timing maturity Business: unit supported sales Momentum in U.S. by recent and international Returning milestonestoMVAD® markets VAD Market Increased System CEclinical Mark clinical trial activity trial now stimulating enrolling interest Enrollm
Slide 38: A New Combined Class of Heart Failure Treatment
A New Combined Class Early Portfolio Medical HeartWare Valtech Tx/CRT Treatment Transcatheter Mechanical Heart Functional Patients VAD VADs HEARTWARE, CHORDAL 38 patients Stage ITransplant Failure remain Class HeartWare: may Valve Surgical Focus Options Company mitral Mid Circulatory and receive II
Slide 39: Synergistic Heart Failure Portfolio
Synergistic Heart HFrEF MCS (mitral) Note: V-Chordal Cardiovalve Cardioband Cardinal longHORNTM CircuLite® mVAD® hVAD® HEARTWARE, VALTECH, 39 HeartWare® Valve Failure Heart HFpEF (tricuspid) Patient MCS Failure CARDIOBAND, Right HVAD, MCS (mitral Population: Reduced Heart Valve MVAD, &Primary tricus
Slide 40: High-Impact Inflection Points
High-Impact 2015 Cardinal Cardioband Valve V-Chordal CardioValve CircuLite MVAD MCS Fully-Implantable FIM Longhorn Initiate HEARTWARE, CHORDAL 40 toCircuLite Cardioband CE U.S. Tricuspid Mitral Surgical Mark Mitral and Study Transseptal Transapical Clinical Endovascular HVAD, Valtech Today Tricuspid
Slide 41: Integration Plan: Valtech and HeartWare
Integration Valtech HeartWare –Anticipate HEARTWARE, CHORDAL delivering Cardinal Leverage Use experienced to operate complementary Recruit core Plan heart and Seamless team HVAD, and Valtech team as clinical 20Opportunities: aremains and integration customer separate, MVAD, logos -25 team market foc
Slide 42: Creating the Technology Leader in Advanced Heart Failure
HeartWare MVAD® repair Sophisticated HEARTWARE, CHORDALof MR System +and Valtech: and CardioValve HVAD, Valtech leading TR expected Creating MVAD, logos a design transformation are to thePAL, emerge and trademarks Technology delivery SYNERGY, asoffirst-line MCS ofsystem Leader Valtech portfolio CIRC
HeartWare International — Merger or Acquisition (September 2015) on 6ix